Home » 2012 » November » 22

Subsequent Entry Biologic Litigation Set to Take Off in Canada

Subsequent Entry Biologic Litigation Set to Take Off in Canada

The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs are derived through the metabolic activity of living organisms and tend to be significantly more variable and structurally complex then chemically synthesized drugs.